Editas founder Katrine Bosley abruptly steps aside from the helm, just ahead of historic CRISPR move
For close to 5 years now Katrine Bosley has led Editas Medicine $EDIT through good times and bad, right to the threshold of dosing its first patient in the premier clinical study for its groundbreaking gene-editing tech.
But she’s not taking the next step with the team.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.